US Patent

US9999593 — Method and composition for treating ocular hypertension and glaucoma

Formulation · Assigned to Asahi Glass Co Ltd · Expires 2029-05-28 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method and composition for treating ocular hypertension and glaucoma using an ophthalmic aqueous composition containing PGF2α analogs.

USPTO Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2α analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogs in an aqueous composition.

Drugs covered by this patent

Patent Metadata

Patent number
US9999593
Jurisdiction
US
Classification
Formulation
Expires
2029-05-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Asahi Glass Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.